Company Aggregate Debt: CASI Pharmaceuticals Inc. (CASI)

The stable management of CASI Pharmaceuticals (CASI) has focused on integrating oncology drugs into government procurement, which triggered a surge in current liabilities. The value of 0.00 shows the latest debt figure. This increase in debt is linked to licensing alliances aimed at launching drugs in China, although business success depends on the speed of regulatory approvals and government drug insurance.

Company Aggregate Debts: CASI Pharmaceuticals (CASI) for 07/04/2022 - 03/14/2026

Analytical breakdowns and data insights for company CASI Pharmaceuticals (CASI)

- price and consensus price forecast:

Stock Price casipharmaceuticals.com|CASI - Price Target Chart

- market capitalization data:

Market Capitalization CASI|CASI - Enterprise Value

- book capitalization data:

Accounting Value per Share CASI Pharmaceuticals|CASI - Book Capitalization|Market-to-Book Ratio casipharmaceuticals.com|CASI - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio CASI Pharmaceuticals|CASI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital casipharmaceuticals.com|CASI - Company Aggregate Debts|Debt to Book Capitalization Ratio CASI|CASI - Company Long-Term Debt|Company Short-Term Debt CASI Pharmaceuticals

Fundamental company analysis:CASI Pharmaceuticals Inc. CASI

Original product of CASI Pharmaceuticals, Inc.

Professional managers utilize fundamental filters to assess an issuer's solvency and the quality of its capital management. The dynamics of total credit obligations reflect the balance between borrowing and repayment, which is critical for CASI Pharmaceuticals (CASI) when financing costly oncology R&D and clinical trials in China, allowing analysts to distinguish organic growth from a dangerous reduction in assets.

Company Aggregate Debt: CASI Pharmaceuticals Inc. (CASI)

Analytical breakdowns and data insights for company CASI Pharmaceuticals (CASI)

Competitors of CASI Pharmaceuticals